Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel.

Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu EB, Swanson PE, Taylor CR, Vyberg M; International Ad Hoc Expert Panel.

Appl Immunohistochem Mol Morphol. 2014 Apr;22(4):241-52. doi: 10.1097/PAI.0000000000000069.

2.

Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.

Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N, Song YJ, Zan LK, Zhang X, Zhou M, Gu YH, Liu T, Hicks DG, Tang P.

Breast Cancer (Auckl). 2012;6:1-8. doi: 10.4137/BCBCR.S8323. Epub 2011 Dec 6.

3.

Osteoporosis after breast cancer chemotherapy: a case report.

Sisti G, Prontera O.

Ochsner J. 2009 Summer;9(2):68-74.

4.

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.

Bauer K, Parise C, Caggiano V.

BMC Cancer. 2010 May 21;10:228. doi: 10.1186/1471-2407-10-228.

5.

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members.

Ann Oncol. 2009 Aug;20(8):1319-29. doi: 10.1093/annonc/mdp322. Epub 2009 Jun 17.

Supplemental Content

Support Center